Additionally, ERK1/2 inhibitor (PD98059) significantly inhibited IL-17A-mediated proliferation, collagen synthesis and secretion, and migration of SSc patient-derived DVSMCs. This evidence concerns the gene IL17A and systemic sclerosis.